In turn, illustrating that perhaps beyond truncal TP53 mutations, we should be cautious in terms of our expectations when comparing primary tumours and ascites-derived cells, especially when separated by extended periods of time and/or chemotherapy regimens. The gene discussed is TP53; the disease is neoplasm.